A case report has been published about a successful rechallenge with an immune checkpoint inhibitor after a patient experienced Guillain-Barré syndrome induced by sintilimab. Other reports have also been released about various cases of patients being rechallenged with immune checkpoint inhibitors after experiencing different side effects. The outcomes of these rechallenges appear to be positive in some cases, but the reports vary in terms of the specific inhibitors and conditions involved.